Literature DB >> 11588308

Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation.

C Wehinger1, C Stöllberger, T Länger, B Schneider, J Finsterer.   

Abstract

BACKGROUND AND
PURPOSE: We sought to assess in outpatients with atrial fibrillation and oral anticoagulation (1) whether the complication rate is influenced by the presence of the risk factors age >65 years, arterial hypertension, diabetes, or previous stroke; (2) whether the complication rate is influenced by the number of additional drugs taken by patients; and (3) whether problems and interventions differ between patients with or without complications.
METHODS: - Clinical characteristics, drugs, problems, interventions, and complications were registered during 2 years.
RESULTS: - Three hundred sixty patients (mean age, 68 years; 43% female) were observed for 383 patient-years. Patients aged >65 years had more serious, life-threatening, or fatal complications (11% versus 5.3%/100 patient-years; P=0.0428) than younger patients. Patients with diabetes had more life-threatening and fatal complications (2.8% versus 0.6%/100 patient-years; P=0.0354) than patients without. The complication rate did not differ regarding the presence of previous stroke or hypertension. Patients who took </=3 drugs had fewer complications than patients who took more (4.3% versus 24.4%/100 patient-years; P=0.0041). Patients with complications complained more of chest (48% versus 28%/100 patient-years; P=0.0113) and abdominal pain (30% versus 13%/100 patient-years; P=0.0057), more frequently failed to keep appointments (134% versus 107%/100 patient-years; P=0.0321), had a higher tracking rate (134% versus 105%/100 patient-years; P=0.0272), and took more additional drugs (4.6 versus 3.5 drugs per day; P=0.0063) than patients with no complications.
CONCLUSIONS: - Patients with increased age or diabetes mellitus or those who take >3 drugs per day have an increased complication rate and thus need especially careful monitoring of oral anticoagulation, including adequate pain control.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588308     DOI: 10.1161/hs1001.097090

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.

Authors:  Waltraud Leiss; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Anne Angelillo-Scherrer; Jacques Cornuz; Martin Banyai; Bernhard Lämmle; Marc Husmann; Michael Egloff; Markus Aschwanden; Nicolas Rodondi; Drahomir Aujesky
Journal:  J Gen Intern Med       Date:  2014-08-21       Impact factor: 5.128

2.  The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study.

Authors:  Chris Burton; Chris Isles; John Norrie; Ruth Hanson; Elaine Grubb
Journal:  Br J Gen Pract       Date:  2006-09       Impact factor: 5.386

Review 3.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?

Authors:  Rik Willems; Derek V Exner
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 5.  Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Authors:  Eric Pautas; Isabelle Gouin-Thibault; Matthieu Debray; Pascale Gaussem; Virginie Siguret
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Outcome of coumarin-therapy in an outpatient setting over a 10-year period: coumarin-therapy in clinical practice.

Authors:  Eva Z Reininghaus; Harald Schmidt; Ingrid Lafer; Georg Gutjahr; Stefan M Schmidt; Bernd Reininghaus; Hans-Peter Kapfhammer; Vinzenz Stepan
Journal:  Wien Klin Wochenschr       Date:  2012-11-06       Impact factor: 1.704

7.  Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.

Authors:  Jeroen Jaspers Focks; Marc A Brouwer; Daniel M Wojdyla; Laine Thomas; Renato D Lopes; Jeffrey B Washam; Fernando Lanas; Denis Xavier; Steen Husted; Lars Wallentin; John H Alexander; Christopher B Granger; Freek W A Verheugt
Journal:  BMJ       Date:  2016-06-15

8.  Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors.

Authors:  F Ben Mbarka; K Ben Jeddou; E Allouche; I Boukhris; N Khalfallah; H Baccar; Z Ouahchi
Journal:  Egypt Heart J       Date:  2018-02-01

Review 9.  Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE).

Authors:  Xin Zhang; Qiyan Cai; Xiaohui Wang; Ke Liao; Changchun Hu; Hong Chen
Journal:  J Thromb Thrombolysis       Date:  2021-03-05       Impact factor: 2.300

10.  Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.